Page last updated: 2024-11-05

triazolam and Heart Failure

triazolam has been researched along with Heart Failure in 1 studies

Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.

Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Rocha, A1
Pinto, ACPN1
Pachito, DV1
Drager, LF1
Lorenzi-Filho, G1
Atallah, ÁN1

Reviews

1 review available for triazolam and Heart Failure

ArticleYear
Pharmacological treatment for central sleep apnoea in adults.
    The Cochrane database of systematic reviews, 2023, 02-27, Volume: 2

    Topics: Acetazolamide; Adult; Aged; Apnea; Buspirone; Carbonic Anhydrase Inhibitors; Disorders of Excessive

2023